Clinical trials

5

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

An Observational, Multinational, In Hospital Evaluation of Catheter Utilization Rates in Female Patients Using Indwelling Urinary Catheters and the PureWick™ Flex Female External Catheter Across Europe and the Middle East

Urinary catheterization is commonly used in hospitalized patients for the management of urinary incontinence, immobilization, and monitoring of urinary output. However, indwelling urinary catheters (IUCs) are associated with clinically significant risks, including catheter-associated urinary tract infections (CAUTIs), other infectious and non-infectious complications, prolonged hospital stay, and increased healthcare costs. The risk of complications increases with the duration of catheterization, highlighting the need for strategies to reduce unnecessary catheter use and minimize catheter dwell time. The PureWick™ Female External Catheter (FFEC) is a non-invasive urine collection device designed to manage urinary incontinence in female patients without the need for an indwelling catheter. By providing an alternative approach to urinary management, it has the potential to reduce reliance on IUCs and associated complications while improving patient comfort and quality of care. This study is a prospective, multinational, observational, sequential two-cohort study conducted in hospitalized adult female patients across Europe and the Middle East. The study aims to evaluate the effect of introducing the PureWick™ FFEC into clinical practice on indwelling urinary catheter utilization rates in routine hospital care. Approximately 240 adult female patients requiring urinary management for incontinence during hospitalization will be enrolled across multiple clinical sites. The study consists of two sequential cohorts within participating sites. In Cohort 1, patients will receive standard care using indwelling urinary catheters only. In Cohort 2, following the introduction of the PureWick™ FFEC, patients will be managed using either the external catheter alone or in combination with indwelling catheters, according to routine clinical practice. The primary objective is to compare indwelling urinary catheter utilization rates before and after the introduction of the PureWick™ FFEC. Catheter utilization is defined as the proportion of inpatient days during which an indwelling catheter is used (catheter-days per patient-days). Secondary objectives include assessment of the occurrence and nature of adverse events, including urinary tract infections, catheter-associated urinary tract infections, incontinence-associated dermatitis, and falls, as well as evaluation of hospital length of stay. Exploratory objectives include assessment of patient and healthcare professional experience, device usability and satisfaction, pain and discomfort, and sleep quality. Participants will be followed from enrollment until hospital discharge or up to 40 days, whichever occurs first. The results of this study are intended to provide real-world evidence on urinary catheter utilization patterns and to inform clinical practice regarding the role of non-invasive urinary management strategies in hospitalized female patients.

Participants needed: 240
Trial details
Age: 18+Biological sex: FemaleType: ObservationalSponsor: Becton, Dickinson and CompanyUpdated: Sep 1, 2026
Eligibility criteria

Adult female subjects ≥ 18 years of age at the time of signing the informed cons... [+5]

Clinically confirmed urinary retention. [+11]

Status: Recruiting

HemoSphere Alta Study

A prospective, non-randomized single arm study using the HemoSphere Alta Advanced Monitoring Platform and associated devices in adult subjects. Data collected from enrolled study subjects will be used for continual device development purposes.

Participants needed: 100
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Becton, Dickinson and CompanyUpdated: Aug 26, 2026Locations: 1
Eligibility criteria

Signed informed consent [+11]

Inability to provide informed consent [+9]

Status: Recruiting

UK PureWick™ At-Home Pilot Study

The UK PureWick™ At-Home Study is being carried out to see how well the PureWick™ Collection System works for women who use it at home instead of a traditional catheter. Traditional catheters are placed inside the body. The PureWick™ Collection System is different, it's placed outside the body . In this study, researchers want to find out: how effective the PureWick™ Collection System is in helping women manage urine collection at home, whether patients prefer using PureWick™ Collection System over the usual catheter, how it affects their sleep, and overall well-being.The PureWick™ Collection System is intended for the treatment of patients who leak urine (called urine incontinence). The PureWick™ Collection System is designed to help manage urine in female patients without needing to insert a urinary catheter into the body.

Participants needed: 95
Trial details
Age: 18+Biological sex: FemaleType: ObservationalSponsor: Becton, Dickinson and CompanyUpdated: Jul 13, 2026Locations: 4
Eligibility criteria

Adult Female Subjects >18 years of age at the time of signing the informed conse... [+4]

Has frequent episodes of bowel incontinence without a fecal management system in... [+9]

Status: Recruiting

The Continuity Study

A before and after interventional cohort study comparing intermittent blood pressure measurement using the oscillometric arm cuff to continuous noninvasive blood pressure (cNIBP) measurement using the VitaWave finger cuffs in subjects undergoing elective surgery in an outpatient setting.

Participants needed: 188
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Becton, Dickinson and CompanyUpdated: Jul 8, 2026Locations: 1
Eligibility criteria

Signed informed consent [+3]

Patient who is known to be pregnant [+6]

Status: Recruiting

Personal BP - CAI Study

A single-center, prospective, observational pilot of the Cerebral Adaptive Index for assessing personalized blood pressure targets

Participants needed: 120
Trial details
Age: 45+Biological sex: AllType: InterventionalSponsor: Becton, Dickinson and CompanyUpdated: Jul 8, 2026Locations: 1
Eligibility criteria

Signed informed consent [+5]

Non-English speaking [+3]